Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? - Wikidata - wikimedia - TriplyDB

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

http://www.wikidata.org/entity/Q40182879

about

Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging Clinical applications of Gallium-68 PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature Tumour-induced osteomalacia: a literature review and a case report Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts Approaching 'Kit-Type' Labelling with (68)Ga: The DATA Chelators.Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer (68)Ga-labeled radiopharmaceuticals for positron emission tomography.68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.Somatostatin receptor immunohistochemistry in neuroendocrine tumors: comparison between manual and automated evaluation.Insulinoma case series: Experience of a tertiary care center.Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy?86Y based PET radiopharmaceuticals: radiochemistry and biological applications Cancer stratification by molecular imaging.Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice.Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry.Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE Stroma targeting nuclear imaging and radiopharmaceuticals.Noninvasive imaging of experimental lung fibrosis.Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate Cyclotron production of (43)Sc for PET imaging Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals.(68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.Integrated FDG-PET/CT imaging is useful in the approach to carcinoid tumors of the lung.Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.Peptide-based imaging agents for cancer detection.PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India.Molecular imaging of neuroendocrine tumors Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.The molecular pathogenesis and management of bronchial carcinoids.Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy.Gallium-labelled peptides for imaging of inflammation.Feasibility and availability of ⁶⁸Ga-labelled peptides.

P2860

Q26778234-457F5E30-C84C-4461-A055-6DCDB7E9721B Q26849276-DB56C3C7-19E7-49E3-8EE2-88BC98DAFDCD Q26992201-27B66AAD-8169-4B33-B802-453A08DFB701 Q28069314-80AB83A8-3C16-4333-9A44-6CFE6D716E00 Q28071483-F0C937BA-BF6C-43C8-8360-070BD12886AF Q28083433-02266C1B-E6A4-428F-A52A-338636C18C21 Q28535054-E32EABC9-AE91-47E0-8F5B-71CC635A9933 Q30938260-958AE1B2-4B51-4DF0-85E9-07A2E72DFE80 Q33665586-8D87257A-AC1C-4A7B-BB8A-0DCF049102E4 Q33704038-BBC2EC80-7985-45C2-9F08-A804814E8CDA Q33915233-C8F9E27E-244F-4001-8819-3EAAD23270A1 Q33917064-4F6D392A-D6B8-4BA4-82BE-43CE924B3604 Q33920975-1AE66FF3-0E84-4F86-A79A-5C2BF8A00A1C Q34119201-A9071EB2-CC3D-4FE5-A716-D7663E3A5E12 Q34121454-EB989561-3A67-4B87-B523-00D3C8193B7B Q34319714-C92ACDBF-2CF4-4A77-818E-9E7A7621E86A Q35217230-2B95BED2-4197-4F8D-A1C2-32C796EB77F2 Q35250409-65992980-0477-4E5D-A5DC-F50033DFD665 Q35380664-F5A71928-EB74-40DF-AC21-AA9AACB35FC8 Q35392459-CB3A8C7F-6F01-4D16-A46A-AC452597C303 Q35394166-B45F28CD-8C53-4E34-A3D7-B81CF7F678B2 Q35478527-4860CBCD-585C-4906-A04E-4C8DDE3F26F5 Q35999606-00480301-5D3D-422C-A160-728A568DFCBA Q36049518-842602FC-56A2-4E89-B78F-ED0D41CB2861 Q36143456-717D8D23-D7E2-4143-912B-85876F68F812 Q36348428-CA1DB2D1-1303-4215-BB4E-DF1AA1A7C90C Q36413831-6C39D75D-BDEF-4F7D-8B63-B7ACE8925EA5 Q36936960-8DDE28A9-DEAE-43AE-BF2C-DD02BFA610FE Q37026964-28A72B6E-2ECD-4E6F-95C4-F59E4E20D904 Q37185143-EDB086A1-23EB-4359-B172-B3C661E78D07 Q37427631-66219E20-7812-483B-9ABB-0C3221E69514 Q37504159-146E0B54-3AC0-46D2-BE07-65E43E89119B Q37585965-AF41C48B-4E02-4215-863E-9797A1E3A070 Q37592451-8FD3FEAF-7AAC-480A-9A36-F548DCAC694B Q37730951-8E19131E-3017-4D0E-A044-3EA5F3874AA3 Q37731335-84E60CFF-7194-4625-89CF-4BE8E7F279CB Q37833109-AF3597E4-26B1-4165-8AB1-887BF5B03AF8 Q37978315-FC6E3CCE-0EC9-41B2-B1ED-E57E36C20DE6 Q37990395-71E7D85B-B71E-4C62-9FDA-4773DA5FD4A1 Q37990396-1CEB3829-50D5-47A6-B064-E58888445D80

P2860

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

http://www.wikidata.org/entity/Q40182879

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Are radiogallium-labelled DOTA ...... belled with other radiometals?

@en

type

label

Are radiogallium-labelled DOTA ...... belled with other radiometals?

@en

prefLabel

Are radiogallium-labelled DOTA ...... belled with other radiometals?

@en

P1433

Q40182879-E2B6A88D-A7B4-40F9-82BC-ED0970C4E04C

P1476

Q40182879-A4488B6C-342A-4211-9CBB-CEFE979474B4

P2093

Q40182879-32CB6BA0-4C76-4DC9-A239-92583AA50813

Q40182879-44FC89C3-9589-4F89-B043-23B8CD27313E

Q40182879-551E7866-C363-44D7-81B3-71E589C69FAE

Q40182879-59F80D84-A153-4F04-B6B0-948B84AAF4C4

Q40182879-72B4429D-6385-4E1B-8B59-DA355B716F52

Q40182879-D49D328B-20D8-48DB-8519-AEA357283D39

Q40182879-DFD0979A-6F85-4ED6-A9BB-CF808601CCF5

P2888

Q40182879-EFC4C130-D0CE-452E-9C7C-138F675EBD18

P304

Q40182879-7256CC58-1384-461D-B768-A0490C73AC44

P31

Q40182879-D0795D4A-DED3-4B65-BD60-DD01CC59B080

P356

Q40182879-D0745080-35DE-4881-8C64-00D7BE812189

P433

Q40182879-0F0A33B2-1C83-499C-B252-03E6C0619241

P478

Q40182879-61F86028-B268-434B-87FC-11E8C832CE38

P577

Q40182879-2DDA48D8-F966-416D-BA48-47BE787EC28E

P5875

Q40182879-6EB0F785-ECE3-4B99-B78A-F400C7C0A04D

P698

Q40182879-417A4D42-BF4A-4275-8F19-8ED5233F8C0C

P356

S00259-006-0317-X

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Are radiogallium-labelled DOTA ...... belled with other radiometals?

@en

P2093

Antunes P

http://www.w3.org/2001/XMLSchema#string

Baum RP

http://www.w3.org/2001/XMLSchema#string

Ginj M

http://www.w3.org/2001/XMLSchema#string

Maecke H

http://www.w3.org/2001/XMLSchema#string

Reubi JC

http://www.w3.org/2001/XMLSchema#string

Waser B

http://www.w3.org/2001/XMLSchema#string

Zhang H

http://www.w3.org/2001/XMLSchema#string

P2888

s00259-006-0317-x

P304

982-993

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-006-0317-X

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6577381

http://www.w3.org/2001/XMLSchema#string

P698

17225119

http://www.w3.org/2001/XMLSchema#string